scholarly journals Case report of metastatic breast cancer mimicking ileal Crohn's disease

2021 ◽  
Vol 87 ◽  
pp. 106408
Author(s):  
Sandeep Maharajh ◽  
Kavi Capildeo ◽  
Mickhaiel Barrow ◽  
Shariful Islam ◽  
Vijay Naraynsingh
Keyword(s):  
Breast Cancer ◽  
Crohn’S Disease ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Crohn's Disease ◽  
Metastatic Breast

Surviving Metastatic Breast Cancer for 18 Years: A Case Report and Review of the Literature

2011 ◽  
Vol 17 (5) ◽  
pp. 521-524 ◽  
Author(s):  
Soley Bayraktar ◽  
Monica T. Garcia-Buitrago ◽  
Erin Hurley ◽  
Stefan Gluck
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Metastatic Breast ◽  
Review Of The Literature

scholarly journals Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report

2020 ◽  
Vol 13 (1) ◽  
pp. 304-308 ◽  
Author(s):  
Alyssa Schlotman ◽  
Adam Stater ◽  
Kyle Schuler ◽  
Judd Heideman ◽  
Vandana Abramson
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Metastatic Breast ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Hepatotoxic Effect ◽  
Er Positive ◽  
Grade 3 ◽  
Experienced Grade

A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic effect. This case report details the timing and nature of this drug-induced liver injury, adding support to an area that has yet to be described adequately in the existing literature.

scholarly journals Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report

2020 ◽  
Vol 13 (2) ◽  
pp. 544-549
Author(s):  
Giacomina Megaro ◽  
Luigi Rossi ◽  
Serena Ceddia ◽  
Marsela Sinjari ◽  
Adele Mannino ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Disease Control ◽  
Endocrine Therapy ◽  
Biological Markers ◽  
Metastatic Breast ◽  
Control Therapy

In the case of our patient, the synergic action of endocrine therapy and chemotherapy plus dual anti-HER2 combination allowed a complete disease control. Therapy should be scheduled by considering the two cancers as individual entities. The approach to breast cancer is changing from being considered a singular disease to a multiform one, according to current research focused on biological markers such as HER2, ERs, and PRs, with important implications in clinical, prognostic, and therapeutic features.

Orbitotemporal Bone Cyst of Metastatic Breast Cancer: Case Report and Literature Review

2019 ◽  
Vol 130 ◽  
pp. 267-270
Author(s):  
Yoshifumi Tao ◽  
Kenji Yagi ◽  
Hirotake Nishimura ◽  
Keijirou Hara ◽  
Shunji Matsubara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Literature Review ◽  
Bone Cyst ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Cancer Case

scholarly journals The potential role of HER 2 upregulation in metastatic breast cancer to the uterus: a case report

2016 ◽  
Vol 4 (10) ◽  
pp. 928-934 ◽  
Author(s):  
Melissa Y. Y. Moey ◽  
Omer A. Hassan ◽  
Christos N. Papageorgiou ◽  
Stephanie L. Schnepp ◽  
John T. Hoff
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Potential Role ◽  
Metastatic Breast ◽  
Her 2
Sign in / Sign up

Export Citation Format

Share Document